Comptes-rendus de sortie des patients : Questions médicales fréquentes
Nom anglais: Patient Discharge Summaries
Descriptor UI:D063886
Tree Number:N06.850.520.308.940.968.750
Termes MeSH sélectionnés :
Proprotein Convertase 9
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Comptes-rendus de sortie des patients : Questions médicales les plus fréquentes",
"headline": "Comptes-rendus de sortie des patients : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Comptes-rendus de sortie des patients : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-11",
"dateModified": "2025-04-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Comptes-rendus de sortie des patients"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Dossiers médicaux",
"url": "https://questionsmedicales.fr/mesh/D008499",
"about": {
"@type": "MedicalCondition",
"name": "Dossiers médicaux",
"code": {
"@type": "MedicalCode",
"code": "D008499",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N06.850.520.308.940.968"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Comptes-rendus de sortie des patients",
"alternateName": "Patient Discharge Summaries",
"code": {
"@type": "MedicalCode",
"code": "D063886",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christine Maria Schwarz",
"url": "https://questionsmedicales.fr/author/Christine%20Maria%20Schwarz",
"affiliation": {
"@type": "Organization",
"name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria."
}
},
{
"@type": "Person",
"name": "Magdalena Hoffmann",
"url": "https://questionsmedicales.fr/author/Magdalena%20Hoffmann",
"affiliation": {
"@type": "Organization",
"name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria. magdalena.hoffmann@medunigraz.at."
}
},
{
"@type": "Person",
"name": "Gerald Sendlhofer",
"url": "https://questionsmedicales.fr/author/Gerald%20Sendlhofer",
"affiliation": {
"@type": "Organization",
"name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria."
}
},
{
"@type": "Person",
"name": "Thomas R Campion",
"url": "https://questionsmedicales.fr/author/Thomas%20R%20Campion",
"affiliation": {
"@type": "Organization",
"name": "Department of Population Health, Weill Cornell Medicine, New York, NY 10065, United States."
}
},
{
"@type": "Person",
"name": "Rebecca Brundin-Mather",
"url": "https://questionsmedicales.fr/author/Rebecca%20Brundin-Mather",
"affiliation": {
"@type": "Organization",
"name": "Department of Critical Care Medicine, University of Calgary, Calgary T2N 4Z6, Alberta, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The role of proprotein convertase subtillisin/kexin type 9 in placental salvage and lipid metabolism in women with preeclampsia.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36603351",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.placenta.2022.12.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.",
"datePublished": "2022-07-06",
"url": "https://questionsmedicales.fr/article/35803317",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.diabres.2022.109983"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of high proprotein convertase subtilisin/kexin type 9 antibody level with poor prognosis in patients with diabetes: a prospective study.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37012310",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-32644-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan.",
"datePublished": "2022-11-24",
"url": "https://questionsmedicales.fr/article/36418110",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5551/jat.63789"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) levels with abnormally high ankle-brachial index in atrial fibrillation.",
"datePublished": "2023-03-16",
"url": "https://questionsmedicales.fr/article/36929300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33963/KP.a2023.0067"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Environnement et santé publique",
"item": "https://questionsmedicales.fr/mesh/D004778"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé publique",
"item": "https://questionsmedicales.fr/mesh/D011634"
},
{
"@type": "ListItem",
"position": 4,
"name": "Méthodes épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D004812"
},
{
"@type": "ListItem",
"position": 5,
"name": "Collecte de données",
"item": "https://questionsmedicales.fr/mesh/D003625"
},
{
"@type": "ListItem",
"position": 6,
"name": "Documents",
"item": "https://questionsmedicales.fr/mesh/D011996"
},
{
"@type": "ListItem",
"position": 7,
"name": "Dossiers médicaux",
"item": "https://questionsmedicales.fr/mesh/D008499"
},
{
"@type": "ListItem",
"position": 8,
"name": "Comptes-rendus de sortie des patients",
"item": "https://questionsmedicales.fr/mesh/D063886"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Comptes-rendus de sortie des patients - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Comptes-rendus de sortie des patients",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Comptes-rendus de sortie des patients",
"description": "Quels diagnostics sont souvent notés dans un compte-rendu ?\nComment le diagnostic est-il confirmé dans le rapport ?\nQuelle est l'importance du diagnostic dans le compte-rendu ?\nLes diagnostics sont-ils classés dans le compte-rendu ?\nComment les diagnostics influencent-ils le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Proprotein+Convertase+9&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Comptes-rendus de sortie des patients",
"description": "Quels symptômes sont souvent mentionnés ?\nComment les symptômes sont-ils évalués ?\nLes symptômes changent-ils après le traitement ?\nLes symptômes sont-ils classés par gravité ?\nComment les symptômes influencent-ils le suivi ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Proprotein+Convertase+9&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Comptes-rendus de sortie des patients",
"description": "Quelles mesures préventives sont recommandées ?\nComment la prévention est-elle abordée dans le rapport ?\nLa prévention est-elle personnalisée ?\nQuels conseils de prévention sont souvent inclus ?\nLa prévention est-elle suivie après la sortie ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Proprotein+Convertase+9&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Comptes-rendus de sortie des patients",
"description": "Quels types de traitements sont documentés ?\nComment les traitements sont-ils justifiés ?\nLes traitements sont-ils suivis d'effets secondaires ?\nComment les traitements sont-ils planifiés ?\nLes traitements sont-ils adaptés après la sortie ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Proprotein+Convertase+9&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Comptes-rendus de sortie des patients",
"description": "Quelles complications peuvent survenir après la sortie ?\nComment les complications sont-elles signalées ?\nLes complications sont-elles documentées dans le rapport ?\nComment prévenir les complications après la sortie ?\nLes complications influencent-elles le suivi ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Proprotein+Convertase+9&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Comptes-rendus de sortie des patients",
"description": "Quels facteurs de risque sont souvent identifiés ?\nComment les facteurs de risque sont-ils évalués ?\nLes facteurs de risque influencent-ils le traitement ?\nLes facteurs de risque sont-ils notés dans le compte-rendu ?\nComment réduire les facteurs de risque après la sortie ?",
"url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Proprotein+Convertase+9&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quels diagnostics sont souvent notés dans un compte-rendu ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les diagnostics incluent des maladies aiguës, chroniques et des complications post-opératoires."
}
},
{
"@type": "Question",
"name": "Comment le diagnostic est-il confirmé dans le rapport ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic est confirmé par des examens cliniques, des tests de laboratoire et des imageries."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du diagnostic dans le compte-rendu ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il guide le suivi médical et les traitements à administrer après la sortie."
}
},
{
"@type": "Question",
"name": "Les diagnostics sont-ils classés dans le compte-rendu ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent classés par ordre de gravité ou de chronologie."
}
},
{
"@type": "Question",
"name": "Comment les diagnostics influencent-ils le traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils déterminent les protocoles de traitement et les médicaments prescrits."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont souvent mentionnés ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, fièvre, fatigue et autres signes cliniques pertinents."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par l'examen physique et les antécédents médicaux du patient."
}
},
{
"@type": "Question",
"name": "Les symptômes changent-ils après le traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le compte-rendu note souvent l'évolution des symptômes post-traitement."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils classés par gravité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être classés en fonction de leur impact sur la santé du patient."
}
},
{
"@type": "Question",
"name": "Comment les symptômes influencent-ils le suivi ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils orientent les recommandations de suivi et les consultations nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mesures incluent vaccinations, conseils diététiques et exercices physiques."
}
},
{
"@type": "Question",
"name": "Comment la prévention est-elle abordée dans le rapport ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est abordée par des recommandations spécifiques basées sur le diagnostic."
}
},
{
"@type": "Question",
"name": "La prévention est-elle personnalisée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent adaptée aux antécédents médicaux et au mode de vie du patient."
}
},
{
"@type": "Question",
"name": "Quels conseils de prévention sont souvent inclus ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils sur l'alimentation, l'exercice et l'arrêt du tabac sont fréquents."
}
},
{
"@type": "Question",
"name": "La prévention est-elle suivie après la sortie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le suivi des mesures préventives est souvent recommandé lors des consultations."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont documentés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent médications, interventions chirurgicales et thérapies physiques."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils justifiés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont justifiés par les diagnostics et l'évolution des symptômes du patient."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils suivis d'effets secondaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les effets secondaires potentiels sont souvent notés pour chaque traitement."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils planifiés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont planifiés en fonction des besoins individuels et des protocoles médicaux."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils adaptés après la sortie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements peuvent être nécessaires en fonction de l'évolution du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après la sortie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, douleurs persistantes et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles signalées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont signalées par des observations cliniques et des tests de suivi."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles documentées dans le rapport ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont souvent documentées pour informer le suivi médical."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications après la sortie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des soins appropriés et le respect des recommandations médicales."
}
},
{
"@type": "Question",
"name": "Les complications influencent-elles le suivi ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent nécessiter des consultations supplémentaires et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont souvent identifiés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et les habitudes de vie."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par l'anamnèse et des tests de dépistage spécifiques."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque influencent-ils le traitement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent orienter les choix thérapeutiques et les recommandations de suivi."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque sont-ils notés dans le compte-rendu ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent notés pour une meilleure gestion des soins futurs."
}
},
{
"@type": "Question",
"name": "Comment réduire les facteurs de risque après la sortie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réduction passe par des changements de mode de vie et un suivi médical régulier."
}
}
]
}
]
}
Preeclampsia is associated with decreased maternal low-density lipoprotein cholesterol (LDL-c), which is essential for fetal growth. The underlying mechanisms for decreased LDL-c in preeclampsia remai...
This is an observational study examining PCSK9 levels in maternal sera, umbilical cord blood, and PCSK9 protein content in placental tissue in three different locations (maternal placental interface, ...
68 parturients with preeclampsia and 55 without preeclampsia were enrolled. Maternal serum LDL-c (116.6 ± 48.9 mg/dL vs 146.1 ± 47.1 mg/dL, p = 0.0045) and PCSK9 (83 [61.8127.6] ng/mL vs 105.3 [83.514...
PCSK9 levels are lower in maternal sera in preeclampsia when compared to controls. Placental PCSK9 protein content in preeclampsia increases from the maternal interface to the umbilical cord; however,...
Cardiovascular benefits of sodium-glucose cotrasporter-2 (SGLT2) inhibitors occur despite a modest increase in low-density lipoprotein cholesterol (LDL-c). We tested whether the effects of chronic SGL...
78 patients with type 2 diabetes (T2D) received empagliflozin 25 mg/d in an open-label design. At enrollment and after 4-week therapy, fasting blood samples were collected for the measurement of plasm...
Plasma PCSK9 was not significantly affected by empagliflozin (-10.7 [-24.1, 2.7] ng/mL). The treatment induced a mild increase in high-density lipoprotein cholesterol (+1.7 [0.5, 3.0] mg/dL), without ...
In patients with T2D, chronic SGLT2 inhibition with empagliflozin has no potentially harmful effects on circulating PCSK9 levels. This finding does not support a pathogenetic role of plasma PCSK9 in t...
In addition to pathogenic autoantibodies, polyclonal autoantibodies with unknown physiological roles and pathogenicity are produced in the body. Moreover, serum antibodies against the proprotein conve...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a powerful low density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This study aimed to describe the...
This was a multicenter, retrospective, and observational study. The clinical characteristics, baseline lipid-lowering therapy, and changes in the lipid profile of patients receiving PCSK9 inhibitor tr...
A total of 296 patients (age 57±13 years, male 73%) who received PCSK9 inhibitor treatments (73.3% alirocumab and 26.7% evolocumab) from 2017 to 2021 were included. Among the patients, 62.8% had histo...
In the real-world practice in Taiwan, the LDL-C reduction efficacy of PCSK9 inhibitors was slightly lower than that reported in the clinical trials. The use of non-standard-dosing PCSK9 inhibitors was...
High ankle-brachial index (ABI) has been associated with increased risk of worse outcomes in the general population. Few data on atrial fibrillation (AF) exist. Experimental data suggest that proprote...
We wanted to investigate the relationship between circulating PCSK9 levels and an abnormally high ABI in patients suffering from AF....
We analyzed data from 579 patients included in the prospective ATHERO-AF study. An ABI≥1.4 was considered high. PCSK9 levels were measured coincidentally with ABI measurement. We used optimized cut-of...
One hundred and fifteen patients (19.9%) had an ABI ≥1.4. The mean (standard deviation [SD]) age was 72.1 (7.6) years, and 42.1% of patients were women. Patients with ABI ≥1.4 were older, more frequen...
In AF patients, PCSK9 levels relate to an abnormally high ABI ≥1.4. Our data suggest PCSK9 role in contributing to vascular calcification in AF patients....
Lipoprotein(a) [Lp(a)] has become an important component of the residual risk of cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors display promising effects in ...
Elevated low-density lipoprotein (LDL) cholesterol levels lead to atherosclerosis and platelet hyperaggregability, both of which are known culprits of arterial thrombosis. Normalization of LDL cholest...
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial sy...
The purpose of this study is to examine the effects of PCSK9 inhibitors and small interfering RNA (siRNA) therapy on LDL-c reduction and major adverse cardiac events (MACE) and mortality by conducting...
Using Pubmed, Embase, Cochrane Library and clinicaltrials.gov until April 2023, we extracted randomized controlled trials (RCTs) of PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisi...
In all, 54 studies with 87,669 participants (142,262 person-years) met criteria for inclusion. LDL-c percent change was reported in 47 studies (n = 62,634) evaluating two PCSK9 inhibitors and siRNA th...
PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisiran) significantly reduced LDL-c by >40% in high-risk individuals. Additionally, both Alirocumab and Evolocumab reduced the risk of ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hyperlipidemia. In discovery of novel small molecules that interfere PCSK9/LDLR...
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a breakthrough in the treatment of hypercholesterolemia. The aim of this study was to perform a multicentre prospective anal...
During the study period (July 2017 to February 2022) 246 patients (mean age 61 ± 11 years, male 73%) who were evolocumab (142/246) or alirocumab (104/246) new users were enrolled in the CERTI (Costo E...
PCSK9i therapy allowed a significant improvement in patients' lipid profile [total cholesterol -35%, P < 0.001; triglycerides -9%, P < 0.05; low-density lipoprotein (LDL) cholesterol -51%, P < 0.001; ...
Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progre...